在动荡的市场环境中，市值15.5亿美元的Structure Therapeutics ADR (GPCR)股价已触及52周低点，跌至25.89美元。根据 InvestingPro ...

Jonathan Van Ness has admitted to using weight-loss medication and feels back in 'control' of eating disorder.

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...

Consumers who take GLP-1 drugs might switch what they eat, but they largely spend the same amount of money on CPG food and ...

We recently published an article titled Jim Cramer Discussed These 7 Stocks. In this article, we are going to take a look at ...

Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Dan Monahan, the exec who led Otsuka’s commercialization of Rexulti and Abilify Maintena, is taking command of the launch of ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...